National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting, 14141 [2015-06122]
Download as PDF
<![CDATA[
14141
Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices
information collection. This is a onetime data collection effort.
CDC will use the information to
examine health systems and
dissemination of health systems
technology. Primary care practices will
use the results to inform their systems
for managing patients with chronic
conditions and to improve the quality of
care delivered. NCHS and CDC will also
use the results to improve technical
assistance to public health partners.
OMB approval is requested for two
years. Participation in the survey is
voluntary and all responses CDC will
de-identify all responses. There are no
costs to respondents other than their
time. The total estimated annualized
burden hours are 429.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Form name
Physician .........................................................
Physician .........................................................
Medical Secretary ...........................................
Physician .........................................................
Cognitive Testing Screener ............................
Cognitive Testing Protocol .............................
NSPCP Screener ...........................................
NSPCP ...........................................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–06159 Filed 3–17–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIAMS.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Arthritis and
Musculoskeletal and Skin Diseases,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIAMS.
Date: April 15–16, 2015.
Time: 6:00 p.m. to 3:45 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 31, Room 4C32, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: John J. O’Shea, MD, Ph.D.,
Scientific Director, National Institute of
VerDate Sep<11>2014
19:00 Mar 17, 2015
Jkt 235001
Arthritis & Musculoskeletal and Skin
Diseases, Building 10, Room 9N228, MSC
1820, Bethesda, MD 20892, (301) 496–2612,
osheaj@arb.niams.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS).
Dated: March 12, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–06122 Filed 3–17–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
SUMMARY:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Number
responses per
respondent
25
15
1,500
473
1
1
1
1
Average
burden per
response
(in hours)
5/60
1.25
10/60
20/60
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
GTF2I Mutations as Genetic Marker for
Prognosis of Thymic Malignancies
Description of Technology: The
present invention describes the
presence of a mutation in the general
transcription factor IIi (GTF2I) gene in
indolent thymic tumors that is rarely
found in more aggressive thymic
tumors.
The invention provides a method of
determining the prognosis of thymic
cancer in a patient by assaying (for
example using PCR based methods) the
genetic material obtained from the
patient tissue to detect a mutation in at
least one copy of GTF2I genetic
sequence; and correlating the presence
of a GTF2I mutation with the prognosis
of a thymic cancer patient, the presence
of the mutation indicating that the
thymic cancer is indolent.
A genetic test will complement the
diagnostic assessment, facilitate
development of a molecular
classification and assessment for the
clinical management of thymic cancers.
Potential Commercial Applications:
• A diagnostic test kit for the
prognosis and clinical management of
thymic cancer.
• Clinical decision whether treatment
is needed (for example, additional
treatment after surgery).
• Therapeutic decision making,
between an aggressive course of
E:\FR\FM\18MRN1.SGM
18MRN1
]]>Agencies
[Federal Register Volume 80, Number 52 (Wednesday, March 18, 2015)]
[Notices]
[Page 14141]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06122]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Board of Scientific Counselors, NIAMS.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, including
consideration of personnel qualifications and performance, and the
competence of individual investigators, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, NIAMS.
Date: April 15-16, 2015.
Time: 6:00 p.m. to 3:45 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 31, Room 4C32, 31
Center Drive, Bethesda, MD 20892.
Contact Person: John J. O'Shea, MD, Ph.D., Scientific Director,
National Institute of Arthritis & Musculoskeletal and Skin Diseases,
Building 10, Room 9N228, MSC 1820, Bethesda, MD 20892, (301) 496-
2612, osheaj@arb.niams.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS).
Dated: March 12, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-06122 Filed 3-17-15; 8:45 am]
BILLING CODE 4140-01-P
